Background We report on an exercise to estimate the prevalence of injecting drug use (IDU) and associated harms in a single primary care trust.
Introduction
The substantial geographical variations in the prevalence of injecting drug use (IDU) and in the nature and patterns of injecting risk require locally specific information and appropriate public health action. 1, 2 In the UK, for example, between cities and primary care trusts (PCTs), there may be at least: 3-fold differences in the prevalence of HCV; a greater than 7-fold difference in the prevalence of IDU; a 20-fold difference in the rate of overdose deaths due to illicit drugs in the general population and greater than 2-fold difference in overdose mortality rates in IDU. 1 -4 In England, there is an interdependence between the information gathered and the intelligence provided to services and policymakers at local and national levels. For instance, national estimates of the prevalence of problem and IDU are obtained by summing across multiple estimates for smaller geographical areas (Regional Government and Drug Action Teams). 5 The data sources for these indirect estimates (such as drug treatment and arrestee data) are reported from agencies managed at a local level, with the information collated often at regional and national levels. The information once analysed is then provided back to local policymakers and is used for resource allocation and priority setting by national and regional policymakers.
Surveillance of blood-borne viruses (BBV) through an unlinked anonymous programme is based on the participation of IDUs at multiple services of drug users supplemented by occasional local surveys within England and Wales. 6 These are organized nationally and provide both national and regional estimates of infection and risk for IDUs, and also contribute to national estimates of the overall extent of HCV and HIV. 7, 8 Reliable and consistent information on probable prevalence of HCV in local populations has not yet been generated. Routine diagnostic HCV testing has poor uptake, so laboratory surveillance cannot provide reliable estimates of HCV prevalence. 9 Statistics on the annual number and trends in the number of overdose deaths are monitored and collected nationally through the Office for National Statistics based on extracts of information provided on the cause of death from death certificates.
10,11 It is well known that IDUs have a substantially higher risk of death, especially through overdose, than the general population. 12, 13 However, there are no ongoing surveys of drug-related mortality in the UK. 14, 15 We report on an exercise to generate key information on IDU and its harms (HCV and HIV prevalence and overdose and overall mortality) in a single local area (Bristol). Bristol is the largest city in South West of England with a population of approximately 400 000. Bristol has a large mix of affluent and deprived areas, with one in seven of small geographical areas called super output areas within Bristol among the most deprived 10% in England and Wales.
Methods
We summarize the methods and data sources used to estimate the following public health measures: (i) prevalence of IDU; (ii) prevalence of HCV and HIV among IDUs and (iii) overdose and overall mortality risk among IDUs.
Prevalence of IDU in Bristol
The prevalence of injecting was estimated using capturerecapture (CRC) methods that have been described in detail elsewhere. 16 -19 These methods analyse an incomplete contingency table showing the overlap between multiple data sources (see Table 1 ) in order to estimate the number in the missing cell. This cell represents the unobserved population, i.e. the number in the target population who have not been 'captured' or recorded by the data sources used in the analysis. 20 We used covariate CRC methods 19, 21 that attempt to fit a single model to the data using covariates to allow for heterogeneity between the data sources. Covariate CRC avoids the multiple model fitting (e.g. separate models for each age group and gender), which traditional stratified CRC uses to address heterogeneity, while also providing estimates for each covariate group. The best fitting model was selected on the basis of standard information criterion and a measure of the difference between observed and expected values (G 2 ). This was used to generate estimates of the unobserved and total population (in combination with the observed data). Confidence intervals (CI) were generated using bootstrap methods. Age group (15 -25, 25 -54) and gender (male, female) were fitted as covariates ( The data extracted and included in the analysis comprised information on injecting status (in the last year from assessment); Bristol resident or homeless in Bristol and identifiers for matching across data sets. The common identifiers were: initials (first character of first name and first character of surname), date of birth, sex, postcode sector of residence and ethnic group. The data sources were collated and matched by SWPHO following a common algorithm for these exercises, 2 e.g. matches included cases with one initial the same and same sex and date of birth; and same initials, sex and month and year of birth.
DIP and PROB were combined into a single criminal justice data source [DIP_PROB] . The LAB data set was too small to be used as a separate data source (n ¼ 15) and so we combined it with the treatment data set [NDT_LAB] . Excluding LAB had no effect on the estimates. This left three main data sources for the analysis. As a sensitivity exercise and audit, we matched the combined 'all record' data set with Avon and Bristol primary care records to identify individuals who were registered with a general practitioner (GP) within Avon, which provided a sub-set of records for re-analysis. Table 1 shows the matched data set by gender and age group for the all records, and the sub-set that were matched to the primary care system.
We estimated the prevalence of IDU in Bristol using covariate CRC based on all the collated records, and only those matched to a primary care record.
Prevalence of HCV (and HIV) in Bristol IDU
Respondent driven sampling (RDS) is a method for recruiting marginal populations in a way that can provide information on potential sampling biases. 22 -24 The methods employed by RDS are explained more fully in refs (22, 23, 25, 26) . Briefly, RDS uses a controlled chain referral recruitment approach that allows, through collection of data on network sizes and chains structure, adjustment for recruitment bias. RDS seeds-the initial recruits-were identified through key informant referrals and street outreach. Participants underwent a computer-assisted interview, provided a dried blood spot (DBS) sample for HCV, HBV and HIV testing, and were asked to recruit other participants from their social network using uniquely numbered date-limited coupons. Participants were offered acknowledgements both for their time and for each eligible person that they gave a coupon to who participated in the study. Recruitment took part over 6 weeks in the spring of 2006. Fieldwork costs (including payments to interviewers, fieldwork coordinator, participants and recruitment sites) were £25 000. Two key elements are the estimation of the equilibrium sample and the target population composition, which is used to derive sample weights that can be applied to the sample in analysis. Information to derive these quantities includes the relationship between, and characteristics of, recruiter and recruited across each wave of sampling, and the size of the sampled participants' network. Since, in theory each person is recruiting respondents into the survey from their network; and as the waves of sampling from these networks increases the overall characteristics of the sample stabilizes. Calculating equilibrium samples and sample weights depends upon solving a series of linear From the RDS survey, we report BBV results, uptake of antibody testing and selected injecting risk behaviours.
Overdose and overall mortality risk in Bristol IDU
We estimated the mortality risk for all of the IDUs matched to the primary care register (see Table 1 ), which also were used in the prevalence estimation study. We matched these records with the local ONS mortality file held within the PCT. All deaths recorded until end 2005 were identified, and the mortality rate was estimated using person years follow-up from 1 January 2004 to date of death or end of follow-up period. Overdose deaths were identified through examining cause of death following standard ONS criteria. 27 We calculated the standardized mortality ratio (SMR) comparing Bristol IDU with age-and sex-matched Bristol general population. . We matched 2348 subjects to the local primary care patient registration. That is, 638 (21%) records of IDUs could not be found and were either 'unregistered' with a local GP, or were misclassified. The characteristics of the total and registered cases were similar: approximately 27% were women, 15% aged under 25 and proportionally more women were aged under 25 than men (23 versus 12%). The main difference was in the level of overlap between the data sources. Thus, for all cases over 50% were found on two or more data sources; whereas for cases that were registered with primary care over 60% were found on two or more data sources. Table 2 shows the IDU prevalence estimates by age group and gender based either on all cases or those registered with primary care. The best fitting model (goodness-of-fit x 2 ¼ 3.3, P ¼ 0.5) included two interactions (between DIP_Prob and NSP and between NSP and DTS). Overall the estimates were 5540 (95% CI: 4710 -6780) for all cases and 3280 (95% CI: 1940 -4610) based on the primary care registered population, and the prevalence of IDU aged 15 -54 was 2.2 and 1.3%, respectively. The 'all-case' estimates suggested a larger proportion of unobserved cases compared with 'registered cases' (46 versus 28%, respectively), especially among young men (60 versus 39%, respectively). The two IDU prevalence estimates (based on all or only primary care registered cases) for men and women were 3.4 and 2.2 and 0.9 and 0.6%, respectively, and for IDU aged ,25 or 25-54 were 1.6 and 0.9% and 2.3 and 1.4%, respectively.
Results

Prevalence of IDU in Bristol
Coverage
In 2005 -06 there were approximately 1500 people receiving opiate substitution therapy (OST) per year-yielding an estimated coverage of 27 -46% IDU in OST. The average annual number of syringes distributed was 615 000 suggesting that each injector received 111 -188 syringes per year. This equates to less than 1 syringe per day even after taking into account the large number of people in OST who may have ceased injecting or at least will have reduced their injecting frequency.
Prevalence of BBV and injecting risk in Bristol IDU
Overall 299 IDU were recruited. After adjustment for sample weights the prevalence of BBV antibody was: 53% hepatitis C; 32% hepatitis B (anti-core) and 0.7% HIV. Key characteristics of the weighted sample were: 27% women; 22% under 25; 18% injecting for less than 5 years; 1 in 2 homeless in last year; 1 in 3 imprisoned in last year; and 1 in 2 injected crack and heroin. Hepatitis B virus vaccination and hepatitis C virus testing coverage were mixed. Over 70% of IDUs in Bristol reported having at least one vaccination. However, nearly one in four of those that were anti-HBc negative (that is still susceptible to infection) did not report any hepatitis B virus vaccination. Over 80% of IDUs reported that they have been tested in the past for hepatitis C virus. But more than half of those found to be hepatitis C virus positive reported having not been diagnosed (either reporting no voluntary confidential HCV test or their last such HCV test was negative) and may be unaware of their infection.
Overdose and overall mortality risk in Bristol IDU
Overall, 35 deaths were identified in Bristol from January 2004 to April 2006 from matching 2348 IDUs against the local mortality file. The underlying cause of death is shown in Fig. 1 : 55% were due to drug overdose; 11% due to suicide and the remainder due to other causes. Table 3 shows the estimated all-cause mortality rate and SMR comparing risk of death among IDU in Bristol and the general population in Bristol. Overall the all-cause mortality rate was 0.75% and the overdose mortality rate was 0.4%. The mortality rate was over 1% among IDU aged over 30 and 
Discussion Main findings
Bristol PCT has a high prevalence of IDU, and IDU in Bristol have a high prevalence of HCV the majority of which is undiagnosed. IDUs in Bristol have a risk of death over seven times higher than the general population, but in general lower than other studies of mortality risk in the literature, which generally suggest a mortality rate of over 1%, and 10 -20 times higher than the general population. 12, 13, 28, 29 We demonstrate that locally specific and useful public health intelligence on injecting and its health consequence can be generated. The large difference between IDU CRC estimates based on records matched to primary care system, or using all records, raises questions over whether misclassification bias leads to an over-estimate when all records are used, which may affect other CRC estimates.
What is already known on this topic CRC exercises to estimate IDU prevalence are regularly conducted in the UK, 2, 5 and are an appropriate method for use in local populations. Anonymous sero-surveillance of BBV, which provide local data for selected sites, is ongoing. 30, 31 The local ONS mortality file also is used regularly for mortality audits by PCTs, though rarely for investigating risk of death among IDU. 14, 32 What this study adds
The value of our study lies primarily with the generation of public health intelligence from integrating different data sources and studies. As a result Bristol PCT increased investment in needle and syringe provision, HCV diagnostic testing, and renewed its efforts to reduce injecting risk and BBV transmission locally. Without the local information showing the scale of the risk the commitment and a sense of urgency by providers and policymakers may not have emerged as quickly. In contrast, the public health message from the mortality study was that the high coverage of OST was improving the health of the population, and led to a local commitment to maintain current levels of provision and increase the uptake of OST.
RDS methods to recruit IDU were used to our knowledge for the first time in the UK (Appendix), and provide a model for further studies in the UK to supplement national sero-surveillance. 24,33 -36 Clearly, PCTs would need expert support in order to conduct a similar exercise, which is now available from Health Protection Agency. In the absence of reliable information on prevalence of BBV and injecting risk behaviour among IDU in their local population an RDS study is the best option to obtain this information.
Matching CRC records to primary care system as a sensitivity test is novel. Misclassification bias (i.e. (a) where records are included that do not fulfil the case definition, or matches between data sources are missed ((b), false negative) or falsely identified ((c), false positive) is a potential problem with CRC, especially in the IDU studies, and which can lead to over-estimation (due to (a) and (b)) or under-estimation (due to (c)). 37 This is a particular problem when partial identifiers are used, and the target population may use false or different names for different data sets. We found that one in five of all the records collected in our exercise could not be matched against the primary care register, none of which were matched to the local ONS mortality file. There was a higher degree of matching between the offending, needle exchange and drug treatment data sources for records that were matched to primary care register than for records that were not matched to primary care, and as a result a lower estimate: 3280 (95% CI: 1940 -4610) compared with 5540 (95% CI: 4710 -6780), respectively, a larger difference than the statistical CI. It is unlikely that there were any false positive matches, after matching to primary care register. The implication, therefore, is either the 21% not matched to the primary care system were genuine cases who were less likely be on more than one data set than people who were registered with primary care, or it reflects misclassification bias ((a) and (b)) and an over-estimation of true prevalence. If the latter is true then many other CRC prevalence estimates in the UK may be over-estimates. Finally, local exercises, such as this study, can provide important additional information that could be used in future to test the consistency and validate national data sets as well as providing important local public health intelligence.
Limitations
There was insufficient external validation of which prevalence estimate (3280 or 5540) is true. The difference matters in relation to estimates of the coverage of local interventions, which range from nearly one in two or one in four people in OST and from 111 or 187 syringes distributed per IDU per year. IDU are a mobile population, so a proportion may not be registered with primary care. However, we do not know what proportion of IDU are not registered with primary care, or whether the unregistered population are less likely to be arrested, in specialist drug treatment or at a needle exchange than their counterparts. Further studies are required to obtain this information to support validation of CRC estimates.
The CRC estimate measures prevalence during 1 year, and assumes that over that period there is no net change in the population size due to migration in or out of the area. Alternative dynamic CRC methods can estimate the change in the population over time; however, they demand a representative data set that record attendance or 'capture' histories over time, which are rarely obtainable in epidemiological studies. 38 We know that annually there are approximately 20 opiate overdose deaths per year in Bristol, which using our IDU prevalence estimates as the denominator yields a mortality rate of 0.3 -0.5%. This is consistent with our estimate of 0.4% generated from the record linkage exercise, providing some confidence/informal validation of the mortality estimates, but is too imprecise to test which IDU estimate is the more likely.
The common and key disadvantage of the methods used is that they are all largely indirect, based on multiple assumptions that may be violated and subject to multiple biases that may give misleading results. We show that failure to account for misclassification bias may over-estimate drug use prevalence. There is no sampling frame from which a representative sample of IDU or problem drug users can be drawn. RDS attempts to adjust for selection bias, and as in our study generated realistic sample weights (Appendix). However, currently there are no external data or formal tests that can be used to validate the results of RDS or CRC or mortality record linkage studies described here. This situation may improve in future, with the development of evidence synthesis methods. 7, 39, 40 
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